Addex terminates phase 2b/3 study of dipraglurant in patients with dyskinesia associated with Parkinsons disease due to slow recruitment rate

Addex Therapeutics Ltd, a clinical-stage pharmaceutical company, announced that it has terminated the phase 2b/3 study evaluating dipraglurant as a potential treatment for dyskinesia associated with Parkinson